BioSpace News Archive

Biomea Fusion, Inc. announced today that BMF-219 displayed remarkable activity in both the Zucker Diabetic Fatty (ZDF) Rat and the Streptozotocin-Induced Diabetes (STZ).

InterVenn Biosciences, the leader in glycoproteomics, today announced that it has named Brian Hogan as Chief Financial Officer.

Simulations Plus, Inc., a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, reported financial results for its first quarter of fiscal 2022, ended November 30, 2021.

CooperCompanies, will present at the J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022.

Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, today announced preclinical data highlighting the potential of its lead product candidate, IMM-1-104, to inhibit tumor growth in NRAS mutant melanoma models.

WishBone Medical, Inc. and SpineGuard, an innovative company that deploys its Dynamic Surgical Guidance sensing technology to secure and streamline the placement of bone implants announced a long-term collaborative partnership with, for exclusive distribution rights of PediGuard® smart spinal drilling devices to children’s hospitals across the United States.

Johnson & Johnson (NYSE: JNJ) (the Company) today announced new results from the largest study to date on the durability of COVID-19 vaccines in the United States (U.S.), showing that a single shot of the Johnson & Johnson COVID-19 vaccine resulted in long-lasting protection for up to six months against COVID-19 breakthrough infections, hospitalizations, and intensive care unit (ICU) admissions.

Glaukos Corporation (NYSE: GKOS), today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the iPRIME™ Viscodelivery System, a sterile, single-use, minimally-invasive device for the delivery of viscoelastic fluid during ophthalmic surgery.

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), wishes to clarify certain disclosures in its press release titled “Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19,” issued on December 29, 2021 that provided an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine.

Petros Pharmaceuticals, Inc., a leading provider of therapeutics for men’s health, announces that President and Chief Commercial Officer Fady Boctor will participate at the H.C. Wainwright Bioconnect 2022 Virtual Conference and the Biotech Showcase 2022.